Pharmacological Strategies to Modulate Symptoms in Autism Spectrum Disorders (ASD)
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 30 November 2025 | Viewed by 20
Special Issue Editor
Interests: 2D-QSAR; 3D-QSAR; Hansch analysis; Free–Wilson; structure–activity relationships; CoMFA; CoMSIA; drug design; molecular docking; molecular dynamics; medicinal chemistry; heterocycles; benzimidazole; organic synthesis; cancer
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
ASD is a neurodevelopmental disorder characterized by persistent challenges in social interaction, communication, and repetitive patterns of behavior. Approximately 75 million people worldwide are affected by ASD, representing about 1% of the global population. The current prevalence of autism among children is 1 in 36. Many individuals benefit from therapeutic interventions aimed at managing co-occurring symptoms, such as anxiety, aggression, hyperactivity, and sleep disturbances. When carefully tailored to individual needs, pharmacological approaches can play a complementary role in improving quality of life.
We invite the scientific community to contribute their research to this Special Issue. We welcome submissions related to ASD, either directly or indirectly, including but not limited to, the following topics:
Synthesis and biological evaluation of new molecules targeting pathways involved in the treatment of ASD or aimed at ameliorating its symptoms.
In-depth computational studies to better understand proteins implicated in the development of ASD.
Molecular modeling studies proposing new small-molecule ligands with a high predicted affinity for ASD-related molecular targets, such as 5-HT receptors and GABA channels, among others.
Development of novel animal, insect, cellular, or other models to study or evaluate pharmacological treatments in ASD.
Biological evaluation of well-established drugs to identify new applications for ASD treatment or improve conditions associated with this disorder.
Extensive bibliometric studies demonstrating strong correlations between autism, its causes, molecular targets, or potential pharmacological interventions.
We look forward to your valuable contributions to advancing the field toward evidence-based pharmacological approaches that support individuals with ASD and their diverse needs.
Dr. Jaime Mella Raipan
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pharmacological treatment of ASD
- neurodevelopmental disorders
- molecular modeling and ASD
- drug discovery for autism
- repurposing drugs for ASD
- 5-HT receptors
- GABAergic system
- TRPC6
- mGluR5
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
